AngioDynamics Eyes Earnings Turnaround as Vascular Demand Rises

Forward-Looking Analysis

Analysts are cautiously optimistic about AngioDynamics’ 2026Q3 earnings performance, with projections indicating revenue in the range of $82–$84 million, reflecting a rebound in interventional product demand. EPS estimates are expected to range between $-0.12 to $-0.08, driven by improved operational efficiencies and gross margin expansion. Bank of America raised its price target to $12 from $10, citing increased procedural volume in oncology and vascular markets. JMP Securities reiterated a Market Outperform rating, forecasting a 5–7% sequential revenue growth as AngioDynamics gains market share in its core therapeutic segments. No major downgrades were reported, though profit recovery is still expected to be modest due to ongoing R&D costs and supply chain headwinds.

Historical Performance Review

In 2026Q2, AngioDynamics reported revenue of $79.43 million and a net loss of $6.35 million, with an EPS of -$0.15. Despite the net loss, the company maintained a strong gross profit of $44.78 million, reflecting stable pricing and controlled manufacturing costs. The quarter marked an improvement from prior periods, with a slight increase in demand for its vascular access and interventional oncology products, though profitability was still impacted by higher operating expenses and R&D investments.

Additional News

In late February 2026, AngioDynamics announced the launch of a next-generation line of vascular closure devices, targeting the growing demand for minimally invasive procedures. The new product line, developed in collaboration with leading interventional radiologists, is expected to enter key U.S. markets by Q4 2026. Additionally, the company’s CEO, James E. Clem, highlighted strategic expansion plans in a recent investor presentation, emphasizing a focus on international market penetration and digital platform development to enhance post-procedure patient monitoring.

Summary & Outlook

AngioDynamics is showing early signs of a recovery in key interventional markets, supported by a modest revenue increase and gross margin expansion. While net income remains negative, EPS is expected to improve due to cost optimization and higher procedural volume. The company's recent product launches and strategic focus on international and digital expansion present growth opportunities. However, ongoing R&D expenditures and supply chain constraints remain key risks. Overall, AngioDynamics is positioned for a cautious but positive earnings report, with upside potential if procedural volumes continue to grow and gross profit stabilizes.